Alternative antibody formats.

Roland E Kontermann
{"title":"Alternative antibody formats.","authors":"Roland E Kontermann","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>During the past two decades, numerous recombinant antibody formats have been designed and produced by genetic engineering, extending and improving the activities of naturally occurring antibodies. However, while whole IgG molecules, antibody fragments and chemically modified derivatives thereof are being used clinically, alternative antibody formats still await regulatory approval. This review summarizes recent progress in the development of alternative antibody formats for therapeutic applications, with an emphasis on molecules that are in clinical testing.</p>","PeriodicalId":50605,"journal":{"name":"Current Opinion in Molecular Therapeutics","volume":"12 2","pages":"176-83"},"PeriodicalIF":0.0000,"publicationDate":"2010-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Molecular Therapeutics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

During the past two decades, numerous recombinant antibody formats have been designed and produced by genetic engineering, extending and improving the activities of naturally occurring antibodies. However, while whole IgG molecules, antibody fragments and chemically modified derivatives thereof are being used clinically, alternative antibody formats still await regulatory approval. This review summarizes recent progress in the development of alternative antibody formats for therapeutic applications, with an emphasis on molecules that are in clinical testing.

备选抗体格式。
在过去的二十年中,通过基因工程设计和生产了许多重组抗体格式,扩展和改进了天然抗体的活性。然而,当整个IgG分子、抗体片段及其化学修饰衍生物被用于临床时,替代抗体格式仍在等待监管部门的批准。本文综述了用于治疗应用的替代抗体格式的最新进展,重点介绍了临床试验中的分子。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Opinion in Molecular Therapeutics
Current Opinion in Molecular Therapeutics 医学-生物工程与应用微生物
自引率
0.00%
发文量
0
审稿时长
>12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信